Paula A Newman-Casey1, Roni M Shtein, Anne L Coleman, Leon Herndon, Paul P Lee. 1. *Department of Ophthalmology & Visual Sciences, University of Michigan School of Medicine, Ann Arbor, MI †Department of Ophthalmology, David Geffen School of Medicine, University of California, Los Angeles, CA ‡Department of Ophthalmology, Duke University School of Medicine, Durham, NC.
Abstract
PURPOSE: To explore why glaucoma patients believe that glaucoma continues to cause vision loss despite the availability of effective treatment. METHODS: Nine focus groups were conducted in 3 geographically and ethnically diverse areas of the United States (Los Angeles, CA; Rochester, MN; Durham, NC) that included 56 participants, 31 with poor vision and 25 with good vision. Content analysis was used to identify important themes. Semiquantitative analysis was used to measure the frequency of each theme. RESULTS: A total of 474 relevant comments were made in the 9 focus groups. Focus groups elicited 305 comments about barriers to glaucoma management including issues with adherence (30%), the doctor-patient relationship (21%), knowledge about glaucoma (19%), personal support systems (19%), and barriers to health care delivery such as cost and insurance (11%). A total of 101 comments were made regarding feelings about glaucoma and 58 comments were made regarding beliefs about disease and treatment. CONCLUSIONS: These focus groups brought up many issues surrounding barriers to glaucoma treatment, perceived susceptibility to glaucoma, perceived benefits to treatment, and the emotional response to living with glaucoma. There is a need to create a more comprehensive chronic disease management approach for patients with glaucoma to address both the concrete and emotional issues identified in these focus group discussions.
PURPOSE: To explore why glaucomapatients believe that glaucoma continues to cause vision loss despite the availability of effective treatment. METHODS: Nine focus groups were conducted in 3 geographically and ethnically diverse areas of the United States (Los Angeles, CA; Rochester, MN; Durham, NC) that included 56 participants, 31 with poor vision and 25 with good vision. Content analysis was used to identify important themes. Semiquantitative analysis was used to measure the frequency of each theme. RESULTS: A total of 474 relevant comments were made in the 9 focus groups. Focus groups elicited 305 comments about barriers to glaucoma management including issues with adherence (30%), the doctor-patient relationship (21%), knowledge about glaucoma (19%), personal support systems (19%), and barriers to health care delivery such as cost and insurance (11%). A total of 101 comments were made regarding feelings about glaucoma and 58 comments were made regarding beliefs about disease and treatment. CONCLUSIONS: These focus groups brought up many issues surrounding barriers to glaucoma treatment, perceived susceptibility to glaucoma, perceived benefits to treatment, and the emotional response to living with glaucoma. There is a need to create a more comprehensive chronic disease management approach for patients with glaucoma to address both the concrete and emotional issues identified in these focus group discussions.
Authors: Michael S Spencer; Ann-Marie Rosland; Edith C Kieffer; Brandy R Sinco; Melissa Valerio; Gloria Palmisano; Michael Anderson; J Ricardo Guzman; Michele Heisler Journal: Am J Public Health Date: 2011-06-16 Impact factor: 9.308
Authors: Betsy Sleath; Susan J Blalock; Jennifer L Stone; Asheley Cockrell Skinner; David Covert; Kelly Muir; Alan L Robin Journal: Br J Ophthalmol Date: 2011-05-24 Impact factor: 4.638
Authors: Betsy Sleath; Susan Blalock; David Covert; Jennifer L Stone; Asheley Cockrell Skinner; Kelly Muir; Alan L Robin Journal: Ophthalmology Date: 2011-12 Impact factor: 12.079
Authors: Gemma C M Rossi; Gian Maria Pasinetti; Luigia Scudeller; Rosella Radaelli; Paolo Emilio Bianchi Journal: Eur J Ophthalmol Date: 2011 Jul-Aug Impact factor: 2.597
Authors: Francis L Weng; Sheenu Chandwani; Karen M Kurtyka; Christopher Zacker; Marie A Chisholm-Burns; Kitaw Demissie Journal: BMC Nephrol Date: 2013-12-01 Impact factor: 2.388
Authors: Paula Anne Newman-Casey; Leslie M Niziol; Chamisa K Mackenzie; Kenneth Resnicow; Paul P Lee; David C Musch; Michele Heisler Journal: Pilot Feasibility Stud Date: 2018-07-23
Authors: Kevin J Schneider; Cecilia N Hollenhorst; Autumn N Valicevic; Leslie M Niziol; Michele Heisler; David C Musch; Stephen M Cain; Paula-Anne Newman-Casey Journal: Ophthalmol Glaucoma Date: 2020-08-08
Authors: David J Miller; Leslie M Niziol; Angela R Elam; Michele Heisler; Paul P Lee; Kenneth Resnicow; David C Musch; Deborah Darnley-Fisch; Jamie Mitchell; Paula Anne Newman-Casey Journal: Ophthalmol Glaucoma Date: 2021-06-30